Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

13. Juni 2025 07:00 ET | Quelle: Arvinas Inc.

Arvinas Presents Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the European Hematology Association 2025 Congress

– ARV-393 demonstrated significant single-agent activity in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type (also known as AITL) and transformed follicular lymphoma – – In...
05. Juni 2025 08:28 ET | Quelle: Arvinas Inc.

Arvinas to Present Preclinical Data for PROTAC BCL6 Degrader, ARV-393, at the 2025 European Hematology Association (EHA) Annual Meeting

– Company to showcase preclinical studies of ARV-393, an investigational oral PROTAC BCL6 degrader, as a single agent in models of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type...
25. Februar 2025 05:45 ET | Quelle: Cicero Diagnostics

Cicero Diagnostics, Inc. Announces the Release of MyReceptiva™ – An Endometriosis Detection Test capable of detecting over 90% of endometriosis cases.

Cicero Diagnostics unveils MyReceptiva™, a $585 non-invasive test detecting over 90% of endometriosis cases, with quick results from an endometrial biopsy.